Active, not recruitingPhase 3NCT04854668

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Studying Cap myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Intervention
Anlotinib hydrochloride capsule(drug)
Enrollment
748 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04854668 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy

← Back to all trials